Hepatitis C infection in a Greek population with inherited bleeding disorders

Γιουλεμέ, Όλγα; Paschos, Paschalis; Katsoula, Anastasia; Panteliadou, Kira; Vakalopoulou, Sofia; Garipidou, Vassilia

doi:10.1111/hae.13427

Cited by 5 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients who achieved SVR, the prevalence of cirrhosis was 12.8% vs 32.6% in patients who did not. This is comparable to the cohort of Greece, where 11/74 (14.9%) of the patients developed advanced fibrosis (higher in patients who did not achieve SVR (56% vs 13%) . In Ireland, 21/106 (19.8%) patients developed cirrhosis .…”

Section: Discussionsupporting

confidence: 72%

“…To date, we did not find any other studies describing the elimination of HCV infection in this subgroup of patients. In Greece, Giouleme et al described the treatment uptake up to the first generation of DAA therapy (telaprevir and boceprevir), with a treatment uptake of 56% . As is demonstrated by our findings, elimination efforts in this group are feasible, but these should be monitored to find every patient …”

Section: Discussionsupporting

confidence: 50%

“…However, in patients not cured, there was a large increase in the number of patients with severe fibrosis based on APRI and FIB-4 scores. 26 As is demonstrated by our findings, elimination efforts in this group are feasible, but these should be monitored to find every patient. , with a treatment uptake of 56%.…”

Section: Treatment Of Hcv Infectionmentioning

confidence: 73%

“…This is comparable to the cohort of Greece, where 11/74 (14.9%) of the patients developed advanced fibrosis (higher in patients who did not achieve SVR (56% vs 13%). 26 In Ireland, 21/106 (19.8%) patients developed cirrhosis. 27 In a combined study of cohort of the UK and the Netherlands, 90/700 (13%) of patients developed end-stage liver disease.…”

Section: Treatment Of Hcv Infectionmentioning

confidence: 99%

See 3 more Smart Citations

Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience

et al. 2019

View full text Add to dashboard Cite

Introduction Patients with haemophilia are one of the subgroups with a high prevalence of hepatitis C virus (HCV) infection. They are a potential target group to eliminate HCV infection thanks to the availability of direct‐acting antiviral (DAA) therapy. Aim To investigate the results of DAA therapy in a cohort of patients with bleeding disorders. Methods This retrospective study was conducted between July 2018 and April 2019. All patients born before 1990 with haemophilia, von Willebrand factor Disease, factor V deficiency, factor VII deficiency or afibrinogenemia were included in this study. Results Of 299 patients, 297 (99.3%) were tested for HCV antibody presence and 211 (71.0%) were positive. Of these, 205 (97.1%) were tested for HCV RNA and 153 (72.1%) were chronically infected. In total, 127 (83.0%) received antiviral therapy, and 110 (71.8%) patients were cured by antiviral treatment. The presence of cirrhosis was significantly higher in patients without a cure for HCV infection when compared to patients who achieved sustained virologic response by treatment or never infected (32.6% vs. 12.8% vs. 0%; P < .001). At the end of follow‐up in 2019, only 14 (9.1%) patients had a remaining HCV infection. Ten (71.4%) were lost to follow‐up, one (7.1%) patient refused, two (14.2%) had comorbidities and one (7.1%) will start treatment soon. Conclusion In this cohort, the elimination targets for HCV infection in 2030 as proposed by the World Health Organization were already reached. Nevertheless, in order to cure every patient, monitoring tools are necessary.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionsupporting

confidence: 50%

Section: Treatment Of Hcv Infectionmentioning

confidence: 73%

Section: Treatment Of Hcv Infectionmentioning

confidence: 99%

See 2 more Smart Citations

Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Acute HCV infection is asymptomatic in most cases and therefore was rarely recognised in PWH during the HCV epidemic. The proportion of HCV-infected PWH in whom the infection did not progress to chronic HCV varies in different reports from 7% to 23%, [24][25][26][27][28][29][30][31] of which most estimates range between 10% and 20%. [24][25][26][27][28]31 These percentages of spontaneous clearance are slightly lower than the average 26% spontaneous clearance rate in other HCV populations.…”

Section: The Natural History Of Hcv Infection In Haemophiliamentioning

confidence: 99%

Viral hepatitis in haemophilia: historical perspective and current management

et al. 2021

View full text Add to dashboard Cite

The introduction of clotting factor concentrates has substantially improved the lives of people with clotting factor deficiencies. Unfortunately, the transmission of blood-borne viral infections through these plasma-derived products led to a huge epidemic of human immunodeficiency virus and viral hepatitis in people with haemophilia (PWH). In a significant proportion of PWH exposed to these viruses, the ensuing decades-long chronic infection resulted in excess morbidity and mortality. Fortunately, developments in the safety of blood products, as well as vaccination and highly effective antiviral treatments have improved the prospects of PWH. The present article reviews the background of the viral hepatitis epidemic in PWH, the natural history of hepatitis B and C infections and their long-term management.

show abstract

Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

Spanoudaki¹,

Papadopoulos²,

Trifylli³

et al. 2022

JMDH

View full text Add to dashboard Cite

Haemophilia is a rare, hereditary bleeding disorder. Clotting factor concentrates were a revolutionary treatment which changed the life of people with haemophilia. However, early generation of clotting factor concentrates, without viral inactivation procedures in the manufacturing process, led to an increased risk of transmission of blood-borne viral infections, mainly due to hepatitis C virus and human immunodeficiency virus. As only 20% of HCV-infected patients clear the infection naturally, chronic HCV infection constitutes a serious health problem and a major cause of chronic liver disease in this group of patients. Fortunately, the use of viral inactivation procedures in the plasma-derived factor concentrates manufacturing process and the availability of alternative treatment options, led to a significant reduction of transfusion-associated viral infections. The advent of multiple, orally administrated, highly effective direct-acting antivirals (DAAs) is changing the natural history of HCV infection in patients with haemophilia as these drugs have an excellent safety profile and achieve very high sustained virological response rates, similar to the general population. Eradication of HCV-infection in patients with haemophilia is feasible via micro-elimination projects.

show abstract

Hepatitis C infection in a Greek population with inherited bleeding disorders

Cited by 5 publications

References 8 publications

Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience

Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience

Viral hepatitis in haemophilia: historical perspective and current management

Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

Contact Info

Product

Resources

About